Personalis Q3 revenue $25.7M (+41% YoY); raises FY 2024 guidance to $83-84M

Personalis, Inc.

2024-Q3 EPS reported -$1.19 revenue$67,814,000

Revenue $25.7M, up 41% YoY; biopharma revenue $15.7M (+96% YoY).
Net loss $39.1M includes $26.0M non-cash warrant expense; cash $143.7M.
Raised FY2024 revenue guidance to $83-84M from $79-81M; Q4 revenue expected $15-16M.
Delivered 945 molecular tests in Q3, a 68% sequential increase.
Raised ~$62.2M net from Tempus warrant exercise and ATM stock sales.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.